Physician profile
Katherine Davoren
NPI 1356610406
$9,269.70
in general payments reported to CMS, 2019-2025
28 companies · $2,752 in 2025
The $2,752 reported for 2025 was more than what 91% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $119 · 2021: $1,465 · 2022: $1,565 · 2023: $1,431 · 2024: $1,938 · 2025: $2,752.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,741 · Education: $379.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,741.30 |
| Education | $379.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,735.22 | 2021-2025 | Farxiga, Lokelma |
| Alexion Pharmaceuticals, INC. | $885.53 | 2021-2025 | Ultomiris, Soliris |
| Bayer Healthcare Pharmaceuticals INC. | $661.09 | 2021-2025 | |
| Vifor Pharma, INC. | $604.34 | 2019-2025 | Veltassa, Korsuva |
| Glaxosmithkline, LLC. | $553.71 | 2021-2025 | Benlysta |
| Otsuka America Pharmaceutical, INC. | $551.36 | 2022-2025 | Jynarque, Voyxact |
| Amgen INC. | $488.96 | 2021-2025 | Tavneos, Aranesp, Parsabiv |
| Boehringer Ingelheim Pharmaceuticals, INC. | $468.50 | 2023-2025 | Jardiance |
| Calliditas Therapeutics US INC. | $434.20 | 2022-2025 | Tarpeyo |
| Fresenius USA Marketing, INC. | $370.95 | 2021-2025 | Velphoro, Velphoro, Korsuva |
| Aurinia Pharma U.S., INC. | $361.21 | 2021-2025 | Lupkynis |
| Opko Pharmaceuticals, LLC | $348.08 | 2021-2025 | Rayaldee |
| Travere Therapeutics, INC. | $347.56 | 2022-2025 | |
| Akebia Therapeutics INC | $209.94 | 2021-2025 | Vafseo, Auryxia |
| Ardelyx, INC. | $201.20 | 2023-2025 | Ibsrela |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $188.15 | 2025 | Ozempic, Wegovy |
| Daiichi Sankyo INC. | $160.29 | 2021 | |
| Horizon Therapeutics Plc | $119.04 | 2021 | |
| Lexicon Pharmaceuticals, INC. | $104.71 | 2023-2024 | Inpefa |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $99.61 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $95.97 | 2025 | |
| Mallinckrodt Hospital Products INC. | $91.03 | 2022-2025 | Terlivaz |
| Alnylam Pharmaceuticals INC. | $55.26 | 2022-2024 | Onpattro |
| Takeda Pharmaceuticals U.S.A., INC. | $50.47 | 2021-2024 | Eohilia |
| Cmp Pharma, INC. | $27.07 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $22.69 | 2022 | |
| Nxstage Medical, INC. | $21.84 | 2019 | |
| Janssen Pharmaceuticals, INC | $11.72 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katherine Davoren listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.